Skip to content

Elena Puerta

3 papers in the library · 19 citations · publishing 2007-2011

Papers

Sort Most recent Most cited

Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Neurodegeneration versus Neuromodulation

Pharmaceuticals July 5, 2011 Elena Puerta, Norberto Aguirre 6 citations

The amphetamine analogue 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is widely abused as a recreational drug due to its unique psychological effects. Of interest, MDMA causes long-lasting deficits in neurochemical and histological markers of the serotonergic neurons in the brain of different animal species. Such deficits include the decline in the activity of tryptophan hydroxylase in...

On the Mechanisms Underlying 3,4-Methylenedioxymethamphetamine Toxicity: The Dilemma of the Chicken and the Egg

Neuropsychobiology 2009 Elena Puerta, Isabel Hervias, Norberto Aguirre

Administration of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) to various experimental animals has been shown to induce a selective damage to serotonergic axon terminals. While a great consensus appears to exist regarding the causative role of reactive oxygen species (ROS) in the mechanisms underlying MDMA toxicity, the source of free radicals is still a matter of debate. While some...

Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats.

European Journal of Pharmacology May 21, 2007 Beatriz Goñi-allo, Elena Puerta, Isabel Hervias et al. 13 citations

Amiloride and several of its congeners known to block the Na(+)/Ca(2+) and/or Na(+)/H(+) antiporters potentiate methamphetamine-induced neurotoxicity without altering methamphetamine-induced hyperthermia. We now examine whether amiloride also exacerbates 3,4-methylenedioxymethamphetamine (MDMA)-induced long-term serotonin (5-HT) loss in rats. Amiloride (2.5 mg/kg, every 2 h x 3, i.p.) given at...